On October 13, 2022 NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody therapies for cancer and inflammatory diseases reported that Dr. Raymond Yu, Director of Preclinical, will present at the 10th Annual Immuno-Oncology Summit 2022 held in Boston, Massachusetts and on October 12-14, 2022 (Press release, NovaRock Biotherapeutics, OCT 13, 2022, View Source [SID1234623195]). Dr. Yu’s oral presentation highlights our highly potent and safe CD137 Bispecific Antibody Platform for the Development of Solid Tumor Therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Session Category: NOVEL STRUCTURES AND FORMATS
Date: Thursday, October 13, 2022, at 11:30EST

Abstract: First-generation CD137 agonists reached limited clinical outcomes due to hepatotoxicity and/or poor efficacy. With a "fit-for-purpose" design, NovaRock developed a CD137 bispecific platform to activate the co-stimulatory pathway through TAA-mediated receptor clustering. These bispecific antibodies reprogram the tumor microenvironment to elicit potent anti-tumor effects without detectable toxicity and long-lasting immunological memory. Additionally, these antibodies have been optimized to facilitate development and manufacturing. The lead antibody NBL-028 is currently in the IND-enabling stage.